News >

Pembrolizumab Approval in Squamous NSCLC Expands Treatment Arsenal

Caroline Seymour
Published: Friday, May 17, 2019

Viola W. Zhu, MD, PhD

Viola W. Zhu, MD, PhD

Platinum-doublet chemotherapy is no longer standard of care for patients with advanced squamous non–small cell lung cancer (NSCLC) following the results of the KEYNOTE-407 trial, which demonstrated an improvement in progression-free survival (PFS) and overall survival (OS) irrespective of PD-L1 expression, explained Viola W. Zhu, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication